Not yet recruiting

N/A

5

 

The Alfred- Melbourne, The Alfred-Melbourne

Neuro-Inflammatory disease

 

 

Completed

N/A

200

 

epidural dexamethasone injection ;epidural methylprednisolone injection

Department of ICU, The third affiliated Hospital of Harbin Medical University; Level of the institution：, None

lumbar pain postoperative

 

 

Completed

N/A

400

 

inhale budesonide suspension ;inject methylprednisolone sodium succinate

the 3rd affiliated hospital of Anhui Medical University (The 1st hospital of Hefei); the 3rd affiliated hospital of Anhui Medical University, self-raised funds about 60%, about 40% raised by Hefei Medical Association

chronic obstructive pulmonary disease

 

 

Recruiting

N/A

125

 

intratympanic methylprednisolone perfusion (0.5ml/day,40mg/ml) ;intravenous methylprednisolone 80mg/day×4day, 40mg/day×3day, 20mg/day×3day ;Not treatment

Nanjing Drum Tower Hosipital, Nanjing University Medical School; Nanjing Drum Tower Hosipital, Nanjing University Medical School, National Science Funds of China

Sudden Sensorineural Hearing Loss

 

 

Not yet recruiting

N/A

100

 

Standard treatment ;Standard treatment and methylprednisolone for injection

Wuhan Pulmonary Hosptial; Wuhan Pulmonary Hosptial, Emergency Project for 2019-nCoV of Ministry of Science and Technology

novel coronavirus pneumonia (COVID-19)

 

 

Not yet recruiting

N/A

1044

 

intravenous use methylprednisolone 40mg qd for 5 days ;observation

West China Hospital, Sichuan University; West China Hospital, Sichuan University, National key research project of China during the 13th five-year plan period

Chronic Obstructive Pulmonary Disease

 

 

Completed

N/A

62

Europe

Methylprednisolone, Urbason

Medical University of Sofia

Graves Ophthalmopathy

02/21

02/21

Not yet recruiting

N/A

180

 

Intravenous methylprednisolone andintratympanic injection ;Intravenous methylprednisolone +intratympanic injection+intravenous of Ginaton ;shock dose hormone group

Eye & ENT Hospital of Fudan University; Eye &ENT Hospital of Fudan University, The 2018 annual science and technology innovation action plan project of Shanghai municipal science and technology commission

the idiopathic sudden deafness with vertigo

 

 

Recruiting

N/A

50

Europe

Solu-Medrol

Copenhagen University Hospital at Herlev

Ulcerative Colitis, Ultrasound Therapy; Complications

09/21

02/22

Not yet recruiting

N/A

110

NA

Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;, Placebo

Qianfoshan Hospital

Methylprednisolone;Dihydroxypropyltheophylline;One Lung Ventilation;Respiratory Dynamics

10/21

12/21

Not yet recruiting

N/A

480

 

6ml (3mg) Budesonide aerosol inhalation for Bid*5 days ;6ml (3mg) Budesonide aerosol inhalation for Bid*9-14 days ;Methylprednisolone 40 mg intravenous drip or oral prednisolone 40 mg, Qd*5 days ;Methylprednisolone 40 mg intravenous drip or oral prednisolone 40 mg, Qd*9-14 days

Hefei First People's Hospital; Hefei First People's Hospital, Anhui Key Research and Development Plan

Chronic obstructive pulmonary disease

 

 

Completed

N/A

170

RoW

Methylprednisolone

Xuanwu Hospital, Beijing

Cerebral Venous Thrombosis

07/24

07/24

Active, not recruiting

N/A

30

Europe

Methylprednisolone

Torben Harsløf, Odense University Hospital

Graves Ophthalmopathy

07/22

07/23

Recruiting

N/A

210

 

Batroxobin + methylprednisolone intravenous injection ;Methylprednisolone intravenous injection + dexamethasone injection ;Batroxobin + methylprednisolone intravenous injection + dexamethasone tympanic injection

The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Tinnitus stimulation non-invasive neuromodulation therapy

Sudden deafness

 

 

Completed

N/A

104

Europe

leg fracture

University Hospital, Clermont-Ferrand

Leg Injuries, Fracture, Edema

12/23

05/24

Not yet recruiting

N/A

30

RoW

Azithromycin, azithromycin 500 mg oral tablet, Methylprednisolone, methylprednisolone 500 mg

Assiut University

Idiopathic Pulmonary Fibrosis

03/24

06/24

Not yet recruiting

N/A

80

NA

Inebilizumab, Rituximab(RTX)

Feng Jinzhou

Neuromyelitis Optica Spectrum Disorders

06/24

06/25

Not yet recruiting

N/A

24

NA

Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP

Feng Jinzhou

Neuromyelitis Optica, Efgartigimod

11/24

05/25

Not yet recruiting

N/A

50

 

Mahuang, Kuxingren, Gancao, Fengfang, Dilong, Chishao, Jiezi, Laifuzi, Zisuzi, Huangqi, Huangqin, Qinghao ;1. All patients will take pulmonary rehabilitation therapy; 2. Patients with hypoxia at rest, will take long-term oxygen therapy; 3. Patients with pulmonary infection will take empirical anti-infective treatment, and targeted anti-infective treatment will be given after obtaining the results of drug sensitivity test. For the dosage of hormones and immunomodulators, our recommendations are summarised below: (1) Glucocorticoid: the initial dose of glucocorticoid can range from oral prednisone (1mg·kg-1·d-1) to intravenous methylprednisolone (500-1000 mg/d) for 3 days, then reduced to prednisone or equivalent dose, gradually reduced to maintenance dose in 4-8 weeks according to the patient's condition and treatment response, and maintained close follow-up; (2) Cyclophosphamide: adhere to the daily use of 2mg, the initial dose is prescribed daily oral 25mg-50mg, and increase 25mg every other week to two weeks, according to this cycle until the maximum dose reaches the daily 150mg; (3) Azathioprine: administered at 2-3 mg·kg-1·d-1. The initial dose is 25-30mg/d, and then 25mg will be increased every 7 to 14 days until the maximum amount of 150mg/d is reached; In addition, if the subjects had taken oral corticosteroids for more than one month before entering the trial, and the hormone had reached the maintenance dose, or if they had taken oral immunomodulators for more than one month before entering the trial, the original drug treatment regimen should not be changed during the clinical observation, the investigators should record it completely and truthfully.

Hospital of Chengdu University of Traditional Chinese Medicine; Beijing University of Chinese Medicine, National Natural Science Foundation of China (No.81973713)

progressive pulmonary fibrosis（PPF）

 

 

Not yet recruiting

N/A

106

 

Induction remission stage: Glucocorticoid + cyclophosphamide; Maintain remission stage: Hormone + azathioprine / methotrexate / mycophenolate mofetil ;Induction remission stage: Methylprednisolone + intravenous cyclophosphamide or rituximab; Maintain remission stage: Hormone + azathioprine / mycophenolate mofetil / rituximab ;Induction: Methylprednisolone + cyclophosphamide + rituximab + plasma exchange; Maintain: Hormone + azathioprine / mycophenolate mofetil / rituximab ;Induction: Methylprednisolone + intravenous cyclophosphamide; Maintain: Hormone + azathioprine / methotrexate / mycophenolate mofetil

Children's Hospital Affiliated to Chongqing Medical University; Children's Hospital Affiliated to Chongqing Medical University, self-financing

ANCA associated glomerulonephritis

 

 

N/A

50

RoW

Inebilizumab, oral immunosuppressant

Xuanwu Hospital, Beijing, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Neuromyelitis Optica Spectrum Disorder

07/25

07/25

Recruiting

N/A

142

Europe

Lidocaine, Methylprednisolone Acetate, Depo-Medrol, Dexamethasone

C.L.A.Vleggeert-Lankamp, Spaarne Gasthuis, Stichting Achmea Gezondheidszor, Posthumus Meyjes Fonds

Sciatica, Sciatica Due to Intervertebral Disc Disorder, Sciatic Radiculopathy

12/25

07/26